Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells

Liping Li, Hong Wang, Eddy S. Yang, Carlos L. Arteaga, Fen Xia

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) family has been implicated in several cancers, including breast, and its members have become the target of novel cancer therapies. In this report, we show a novel link between erlotinib, a potent EGFR inhibitor, DNA damage, and homology-directed recombinational repair (HDR) in human breast cancer cells. Erlotinib suppresses HDR. This is not secondary to erlotinib-mediated changes in cell cycle and is associated with increased γ-H2AX foci, which is an in situ marker of chromosomal double-strand breaks. Both Rad51 and BRCA1 are essential components of the HDR machinery. Consistent with decreased HDR in erlotinib-treated cells, erlotinib also attenuates DNA damage-induced Rad51 foci and results in cytoplasmic retention of BRCA1. As BRCA1 is a shuttling protein and its nuclear function of promoting HDR is controlled by its subcellular localization, we further show that targeted translocation of BRCA1 to the cytoplasm enhances erlotinib sensitivity. These findings suggest a novel mechanism of action of erlotinib through its effects on the BRCA1/HDR pathway. Furthermore, BRCA1/HDR status may be an innovative avenue to enhance the sensitivity of cancer cells to erlotinib.

Original languageEnglish (US)
Pages (from-to)9141-9146
Number of pages6
JournalCancer Research
Volume68
Issue number22
DOIs
StatePublished - Nov 15 2008

Fingerprint

Recombinational DNA Repair
Chromosome Breakage
Breast Neoplasms
Epidermal Growth Factor Receptor
DNA Damage
Erlotinib Hydrochloride
Nuclear Proteins
Neoplasms
Cell Cycle
Cytoplasm

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. / Li, Liping; Wang, Hong; Yang, Eddy S.; Arteaga, Carlos L.; Xia, Fen.

In: Cancer Research, Vol. 68, No. 22, 15.11.2008, p. 9141-9146.

Research output: Contribution to journalArticle

Li, Liping ; Wang, Hong ; Yang, Eddy S. ; Arteaga, Carlos L. ; Xia, Fen. / Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. In: Cancer Research. 2008 ; Vol. 68, No. 22. pp. 9141-9146.
@article{d8ee79f249bb4b3285d9bef7e5b34948,
title = "Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells",
abstract = "The epidermal growth factor receptor (EGFR) family has been implicated in several cancers, including breast, and its members have become the target of novel cancer therapies. In this report, we show a novel link between erlotinib, a potent EGFR inhibitor, DNA damage, and homology-directed recombinational repair (HDR) in human breast cancer cells. Erlotinib suppresses HDR. This is not secondary to erlotinib-mediated changes in cell cycle and is associated with increased γ-H2AX foci, which is an in situ marker of chromosomal double-strand breaks. Both Rad51 and BRCA1 are essential components of the HDR machinery. Consistent with decreased HDR in erlotinib-treated cells, erlotinib also attenuates DNA damage-induced Rad51 foci and results in cytoplasmic retention of BRCA1. As BRCA1 is a shuttling protein and its nuclear function of promoting HDR is controlled by its subcellular localization, we further show that targeted translocation of BRCA1 to the cytoplasm enhances erlotinib sensitivity. These findings suggest a novel mechanism of action of erlotinib through its effects on the BRCA1/HDR pathway. Furthermore, BRCA1/HDR status may be an innovative avenue to enhance the sensitivity of cancer cells to erlotinib.",
author = "Liping Li and Hong Wang and Yang, {Eddy S.} and Arteaga, {Carlos L.} and Fen Xia",
year = "2008",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-08-1127",
language = "English (US)",
volume = "68",
pages = "9141--9146",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells

AU - Li, Liping

AU - Wang, Hong

AU - Yang, Eddy S.

AU - Arteaga, Carlos L.

AU - Xia, Fen

PY - 2008/11/15

Y1 - 2008/11/15

N2 - The epidermal growth factor receptor (EGFR) family has been implicated in several cancers, including breast, and its members have become the target of novel cancer therapies. In this report, we show a novel link between erlotinib, a potent EGFR inhibitor, DNA damage, and homology-directed recombinational repair (HDR) in human breast cancer cells. Erlotinib suppresses HDR. This is not secondary to erlotinib-mediated changes in cell cycle and is associated with increased γ-H2AX foci, which is an in situ marker of chromosomal double-strand breaks. Both Rad51 and BRCA1 are essential components of the HDR machinery. Consistent with decreased HDR in erlotinib-treated cells, erlotinib also attenuates DNA damage-induced Rad51 foci and results in cytoplasmic retention of BRCA1. As BRCA1 is a shuttling protein and its nuclear function of promoting HDR is controlled by its subcellular localization, we further show that targeted translocation of BRCA1 to the cytoplasm enhances erlotinib sensitivity. These findings suggest a novel mechanism of action of erlotinib through its effects on the BRCA1/HDR pathway. Furthermore, BRCA1/HDR status may be an innovative avenue to enhance the sensitivity of cancer cells to erlotinib.

AB - The epidermal growth factor receptor (EGFR) family has been implicated in several cancers, including breast, and its members have become the target of novel cancer therapies. In this report, we show a novel link between erlotinib, a potent EGFR inhibitor, DNA damage, and homology-directed recombinational repair (HDR) in human breast cancer cells. Erlotinib suppresses HDR. This is not secondary to erlotinib-mediated changes in cell cycle and is associated with increased γ-H2AX foci, which is an in situ marker of chromosomal double-strand breaks. Both Rad51 and BRCA1 are essential components of the HDR machinery. Consistent with decreased HDR in erlotinib-treated cells, erlotinib also attenuates DNA damage-induced Rad51 foci and results in cytoplasmic retention of BRCA1. As BRCA1 is a shuttling protein and its nuclear function of promoting HDR is controlled by its subcellular localization, we further show that targeted translocation of BRCA1 to the cytoplasm enhances erlotinib sensitivity. These findings suggest a novel mechanism of action of erlotinib through its effects on the BRCA1/HDR pathway. Furthermore, BRCA1/HDR status may be an innovative avenue to enhance the sensitivity of cancer cells to erlotinib.

UR - http://www.scopus.com/inward/record.url?scp=56449098784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449098784&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-1127

DO - 10.1158/0008-5472.CAN-08-1127

M3 - Article

C2 - 19010885

AN - SCOPUS:56449098784

VL - 68

SP - 9141

EP - 9146

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -